Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 9/20 | 0.62 |
| ▸ | CASP1 | P29466 | 2/20 | 0.51 |
| ▸ | BACE1 | P56817 | 2/20 | 0.49 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL812941 | 0.90 | CASP1 (0.61) | OPRD1CASP1BACE1BACE2 | |
| SCHEMBL23931322 | 0.90 | CASP1 (0.61) | OPRD1CASP1BACE1BACE2 | |
| SCHEMBL29408005 | 0.88 | OPRD1 (0.68) | OPRD1CASP1BACE1BACE2OPRM1 | |
| SCHEMBL31404908 | 0.86 | OPRD1 (0.66) | OPRD1CASP1BACE1BACE2OPRM1 | |
| SCHEMBL4735755 | 0.85 | OPRD1 (0.65) | OPRD1CASP1BACE1BACE2OPRM1 | |
| SCHEMBL1170338 | 0.85 | OPRD1 (0.60) | OPRD1CASP1BACE1BACE2OPRM1 | |
| SCHEMBL29409609 | 0.85 | OPRD1 (0.64) | OPRD1CASP1BACE1BACE2OPRM1 | |
| SCHEMBL2037941 | 0.83 | CASP1 (0.67) | CASP1 | |
| SCHEMBL4735748 | 0.82 | OPRD1 (0.61) | OPRD1CASP1BACE1BACE2OPRM1 | |
| SCHEMBL30079821 | 0.81 | OPRD1 (0.58) | OPRD1BACE1BACE2OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200048306-A1 | PRODRUG OF AN ICE INHIBITOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-02-13 | — | — | US | disclosed |
| US-20180327449-A1 | PRODRUG OF AN ICE INHIBITOR | VERTEX PHARMACEUTICALS INCORPORATED | 2018-11-15 | — | — | US | disclosed |
| US-9994613-B2 | Prodrug of an ICE inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170022249-A1 | PRODRUG OF AN ICE INHIBITOR | VERTEX PHARMACEUTICALS INCORPORATED | 2017-01-26 | — | — | US | disclosed |
| US-9487555-B2 | Prodrug of an ice inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-11-08 | — | — | US | disclosed |
| US-9156880-B2 | Prodrug of an ice inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-10-13 | — | — | US | disclosed |
| US-20150284426-A1 | PRODRUG OF AN ICE INHIBITOR | VERTEX PHARMACEUTICALS INCORPORATED | 2015-10-08 | — | — | US | disclosed |
| EP-2270005-B1 | Prodrug of an ice inhibitor | VERTEX PHARMA (US) | 2015-07-08 | — | — | EP | disclosed |
| EP-2773341-A2 | COMPOSITIONS COMPRISING NECROSIS INHIBITORS, SUCH AS NECROSTATINS, ALONE OR IN COMBINATION, FOR PROMOTING AXON REGENERATION AND NERVE FUNCTION, THEREBY TREATING CNS DISORDERS | Massachusetts Eye & Ear Infirmary (US) | 2014-09-10 | — | — | EP | disclosed |
| US-8691848-B2 | Inhibitors of caspases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-04-08 | — | — | US | disclosed |
| EP-0944645-A1 | INHIBITORS OF INTERLEUKIN-1beta CONVERTING ENZYME | Vertex Pharmaceuticals Incorporated (US) | 1999-09-29 | — | — | EP | disclosed |
| WO-1999047545-A2 | INHIBITORS OF CASPASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1999-09-23 | — | — | WO | disclosed |
| EP-0942925-A2 | INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | Vertex Pharmaceuticals Incorporated (US) | 1999-09-22 | — | — | EP | disclosed |
| WO-1999046248-A1 | 1,2-DIAZEPANE DERIVATIVES AS INTERLEUKIN-1BETA CONVERTING ENZYME INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1999-09-16 | — | — | WO | disclosed |
| US-5874424-A | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1999-02-23 | — | — | US | disclosed |
| US-5843904-A | Inhibitors of interleukin-1βconverting enzyme | VERTEX PHARMACEUTICALS, INC. (US) | 1998-12-01 | — | — | US | disclosed |
| EP-0869967-A2 | INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | Vertex Pharmaceuticals Incorporated (US) | 1998-10-14 | — | — | EP | disclosed |
| WO-1998024805-A1 | INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024804-A2 | INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1998-06-11 | — | — | WO | disclosed |
| WO-1997022619-A2 | INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1997-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048306-A1 | PRODRUG OF AN ICE INHIBITOR | CASP1, MCL1, IL1B | OPRD1 2719/4885CASP1 1/4885BACE1 15/4885 |
| US-20180327449-A1 | PRODRUG OF AN ICE INHIBITOR | CASP1, MCL1, IL1B | OPRD1 2719/4885CASP1 1/4885BACE1 15/4885 |
| US-20170022249-A1 | PRODRUG OF AN ICE INHIBITOR | CASP1, MCL1, IL1B | OPRD1 2719/4885CASP1 1/4885BACE1 15/4885 |
| US-20150284426-A1 | PRODRUG OF AN ICE INHIBITOR | CASP1, MCL1, IL1B | OPRD1 2719/4885CASP1 1/4885BACE1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.